LENZ Therapeutics Inc (LENZ)

Currency in USD
18.14
-0.45(-2.42%)
Closed·
18.04-0.10(-0.55%)
·
LENZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.0719.23
52 wk Range
14.4350.40
Key Statistics
Prev. Close
18.59
Open
18.71
Day's Range
18.07-19.23
52 wk Range
14.43-50.4
Volume
1.2M
Average Volume (3m)
1.18M
1-Year Change
-19.0179%
Book Value / Share
6.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LENZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.71
Upside
+196.11%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

LENZ Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

LENZ Therapeutics Inc Company Profile

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

LENZ Therapeutics Inc Earnings Call Summary for Q3/2025

  • LENZ Therapeutics reported Q3 2025 net loss of $0.59 per share with operating expenses up 44% to $31.4M, causing stock to drop 9.38% to $25.42 despite VIZ eye drop launch
  • VIZ, LENZ's FDA-approved treatment for presbyopia, secured over 5,000 prescriptions in its first month with full pharmacy availability expected by mid-November
  • SG&A expenses surged 116% quarter-over-quarter to $27.6M while R&D expenses decreased 58% to $3.8M; company maintains strong $324M cash position
  • Management projects $80-100M commercial spend for 2026 and plans Q1 2026 direct-to-consumer campaign featuring Sarah Jessica Parker
Last Updated: 05/11/2025, 16:32
Read Full Transcript

Compare LENZ to Peers and Sector

Metrics to compare
LENZ
Peers
Sector
Relationship
P/E Ratio
−9.6x−9.8x−0.6x
PEG Ratio
−0.20−0.140.00
Price/Book
2.9x2.3x2.6x
Price / LTM Sales
32.5x5.9x3.4x
Upside (Analyst Target)
207.7%49.7%41.3%
Fair Value Upside
Unlock−6.9%4.9%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 53.71
(+196.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy56.00+208.71%-MaintainOct 27, 2025
Piper Sandler
Buy67.00+269.35%51.00MaintainOct 10, 2025
H.C. Wainwright
Buy56.00+208.71%48.00MaintainAug 22, 2025
H.C. Wainwright
Buy56.00+208.71%48.00MaintainAug 04, 2025
H.C. Wainwright
Buy56.00+208.71%48.00MaintainAug 01, 2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.59 / -0.40
Revenue / Forecast
12.50M / --
EPS Revisions
Last 90 days

LENZ Income Statement

People Also Watch

409.24
SNDK
+5.53%
336.63
MU
+0.98%
12.820
ONDS
-5.46%
13.72
JANX
-2.83%

FAQ

What Is the LENZ Therapeutics (LENZ) Premarket Price Today?

The LENZ Therapeutics (LENZ) premarket price is 18.76. Premarket price change units: 0.17. Premarket percentage change: 0.91%. Premarket volume: 3,010.00. Current date: 16 Jan 2026. Previous close: 18.59

What Stock Exchange Does LENZ Therapeutics Trade On?

LENZ Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for LENZ Therapeutics?

The stock symbol for LENZ Therapeutics is "LENZ."

What Is the LENZ Therapeutics (LENZ) Afterhours Price Today? (Afterhours variable test: 18.04) Current Date: 16 Jan 2026

After hours price: 18.04. After hours price change (units): -0.10. Price change percentage: -0.55%

What Is the LENZ Therapeutics Market Cap?

As of today, LENZ Therapeutics market cap is 581.68M.

What Is LENZ Therapeutics's Earnings Per Share (TTM)?

The LENZ Therapeutics EPS (TTM) is -2.11.

From a Technical Analysis Perspective, Is LENZ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has LENZ Therapeutics Stock Split?

LENZ Therapeutics has split 1 times.

How Many Employees Does LENZ Therapeutics Have?

LENZ Therapeutics has 11 employees.

What is the current trading status of LENZ Therapeutics (LENZ)?

As of 16 Jan 2026, LENZ Therapeutics (LENZ) is trading at a price of 18.14, with a previous close of 18.59. The stock has fluctuated within a day range of 18.07 to 19.23, while its 52-week range spans from 14.43 to 50.40.

What Is LENZ Therapeutics (LENZ) Price Target According to Analysts?

The average 12-month price target for LENZ Therapeutics is USD53.71429, with a high estimate of USD62 and a low estimate of USD36. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +196.11% Upside potential.

What Is the LENZ Premarket Price?

LENZ's last pre-market stock price is 18.76. The pre-market share volume is 3,010.00, and the stock has decreased by 0.17, or 0.91%.

What Is the LENZ After Hours Price?

LENZ's last after hours stock price is 18.04, the stock has decreased by -0.10, or -0.55%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.